(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 September 2013 (06.09.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/130573 A1

(51) International Patent Classification:
C07D 231/56 (2006.01)

(21) International Application Number:
PCT/US2013/027979

(22) International Filing Date:
27 February 2013 (27.02.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/605,572 1 March 2012 (01.03.2012) US

(71) Applicant: **ARRAY BIOPHARMA INC.** [US/US]; 3200 Walnut Street, Boulder, Colorado 80301 (US).

(72) Inventors: **ARRIGO, Alisha B.**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **CORSON, Donald T.**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **MANNILA, Coralee G.**; c/o Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US).

(74) Agents: **MASTOUS, Sarah S.** et al.; Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: CRYSTALLINE FORMS OF 1- (3 -TERT-BUTYL- 1 - P-TOLYL- 1H- PYRAZOL- 5 -YL) -3- (5-FLUORO-2- (1- (2 - HYDROXYETHYL) - INDAZOL- 5 -YLOXY) BENZYL) UREA HYDROCHLORIDE



(I)

(57) Abstract: Provided herein is a hydrogen chloride salt of 1 -(3-/t?r/-butyl-l-p-tolyl-lH-pyrazol-5- yl)-3-(5-fluoro-2-(l-(2-hydroxyethyl)-1 H-indazol-5-yloxy)benzyl)urea, crystalline forms of l-(3-½^butyl- 1 ^-tolyl-lH-pyrazol-5-yl)-3-(5-fluoro-2-(l-(2-hydroxyethyl)-lH-indazol-5- yloxy)benzyl)urea hydrochloride, processes for the preparation of said crystalline forms, pharmaceutical compositions containing a crystalline form of l-(3-r<i/-r-butyl-l-p-tolyl-lH- pyrazol-5-yl)-3-(5-fluoro-2-(l-(2-hydroxyethyl)-lH-indazol-5-yloxy)benzyl)urea hydrochloride Form B, processes for the preparation of said compositions, pharmaceutical compositions prepared by said methods, and the use of said compositions in the treatment of various diseases and disorders.

WO 2013/130573 A1